Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-06-28
2011-06-28
Nickol, Gary B. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S273100
Reexamination Certificate
active
07968096
ABSTRACT:
This invention relates to a method for treatment of latentToxoplasma gondiiinfection. The invention provides for the use of Hsp90 inhibitors for treatment of latentToxoplasma gondiiinfection, particularly in an immunocompromised subject. Also provided is a screening method for identifying compounds useful for treating latentToxoplasma gondiiinfection.
REFERENCES:
patent: 5284656 (1994-02-01), Platz et al.
patent: 5443791 (1995-08-01), Cathcart et al.
patent: 5451569 (1995-09-01), Wong et al.
patent: 5708158 (1998-01-01), Hoey
patent: 2001/0044416 (2001-11-01), McCluskie et al.
Carme et al. , Journal of Clinical Microbiology, vol. 40, No. 11, pp. 4037-4044, Nov. 2002.
Kamal et al. (Trends in Molecular Medicine, vol. 10, No. 6, pp. 283-290, Jun. 2004 ).
Fachinformation. Cisplatin 0,5 mg/ml Lösung medac. 2003:1-5. German.
Weiss LM et al., Bradyzoite development inToxoplasma gondiiand the hsp70 stress response. Infect Immun. Jul. 1998;66(7):3295-302.
Abuchowski A et al., Soluble polymer-enzyme adducts, inEnzymes As Drugs, Hocenberg and Roberts, eds., Wiley Interscience, New York, NY 1981, pp. 367-383.
Adjei A et al., Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers,Pharm. Res. 7(6):565-569 (1990).
Adjei A et al., Bioavailability of leuprolide following intratracheal administration to beagle dogs,Intern. J. Pharm. 61(1-2):135-144 (1990).
Ahn HJ et al., Molecular cloning of the 82-kDa heat shock protein (Hsp90) ofToxoplasma gondiiassociated with the entry into and growth in host cells,Biochem. Biophys. Res. Comm. 311:654-659 (2003).
Angel So et al., Organellar targeting and expression analysis ofToxoplasma gondiiHsp 90 during bradyzoite development,Rev. Inst. Med. trop. S. Paulo, Nov. 2003, 45(supp1.13:35-36. ISSN 0036-4665.
Bisht KB et al., Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity,Cancer Res. 63:8984-8995 (2003).
Bonne W et al., Stage-specific expression of a selectable marker inToxoplasma gondiipermits selective inhibition of either tachyzoites or bradyzoites.Mol Biochem Parasitol. Sep. 1997;88(1-2):115-26.
Boothroyd JC et al., Genetic and biochemical analysis of development inToxoplasma gondii, Philos. Trans. R. Soc. Lond. B. Biol. Sci. 352:1347-1354 (1997).
Braquet P et al., Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig,J. Cardiovasc. Pharmacol. 13(Suppl. 5):S143-S146 (1989).
Debs RJ et al., Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats,J. Immunol. I40(10):3482-3488 (1988).
Echeverria PC et al.,Toxoplasma gondiiHsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated.J Mol Biol. Jul. 22, 2005;350(4):723-34.
GenBank Database Accession No. AY344115.
Gorlich D et al., Transport between the cell nucleus and the cytoplasm,Ann. Rev Cell Dev. Biol. 15:607-660 (1999).
Graefe SE et al., Inhibition of Hsp90 inTrypanosoma cruziinduces a stress response but no stage differentiation,Eukaryotic Cell1(6):936-943 (2002).
Hubbard RC et al., Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin,Ann. Intern. Med. 111(3):206-212 (1989).
Israelski DM et al., Toxoplasmosis in the non-AIDS immunocompromised host,Curr. Clin. Top. Infect. Dis. 13:322-356 (1993).
Kamal A et al., Therapeutic and diagnostic implications of Hsp90 activation,Trends Mol. Med. 10(6):283-290 (2004).
Kang Ki et al., In vivo functional protein-protein interaction: nuclear targeted Hsp90 shifts cytoplasmic steroid receptor mutants into the nucleus,Proc. Nat'l. Acad. Sci. USA 91:340-344 (1994).
Kasper LH et al., Recognition and characterization of stage-specific oocyst/sporozoite antigens ofToxoplasma gondiiby human antisera,J. Clin. Invest. 75:1570-1577 (1985).
Luft BJ et al., Toxoplasmic encephalitis in AIDS.Clin Infect Dis. Aug. 1992;15(2):211-22.
Lyons RE et al.,Toxoplasma gondiitachyzoite-bradyzoite interconversion,Trends Parasitol. 18(5):198-201 (2002).
Matrajt M et al., Amino-terminal control of transgenic protein expression levels inToxoplasma gondii, Mol. Biochem. Parasitol. 120:285-289 (2002).
Matrajt M et al., Identification and characterization of differentiation mutants in the protozoan parasiteToxoplasma gondii, Mol. Microbiol. 44(3):735-747 (2002).
Nagel SD et al., The alpha- and beta-tubulins ofToxoplasma gondiiare encoded by single copy genes containing multiple introns,Mol. Biochem. Parasitol. 29(2-3):261-273 (1988).
Neckers L, Effects of geldanamycin and other naturally occurring small molecule antagonists of heat shock protein 90 on HER2 protein expression,Breast Dis. 11:49-59 (1999).
Nemoto T et al., Mechanism of dimer formation of the 90-kDa heat-shock protein,Eur. J. Biochem. 233(1):1-8 (1995).
Newmark J et al., Preparation and Properties of Adducts of Streptokinase and Streptokinase-Plasmin Complex with Polyethylene Glycol and Pluronic Polyol F38,J. Appl. Biochem. 4:185-189 (1982).
Oeswein JQ et al., Aerosolization of proteins,Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado (1990).
Robbins J et al., Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence,Cell64(3):615-623 (1991).
Rojas PA et al., Expression of a cDNA encoding aToxoplasma gondiiprotein belonging to the heat-shock 90 family and analysis of its antigenicity,FEMS Microbiol. Lett. 190(2):209-213 (2000).
Sausville EA, Geldanamycin analogs,J. Chemotherap. 16(Suppl. 4):68-69 (2004).
Segui-Simarro JM et al., Hsp70 and Hsp90 change their expression and subcellular localization after microspore embryogenesis induction inBrassica napusL.,J. Struct. Biol. 142(3):379-391 (2003).
Smith RM et al., Pulmonary deposition and clearance of aerosolized alpha-l-proteinase inhibitor administered to dogs and to sheep,J. Clin. Invest. 84:1145-1154 (1989).
Soete M et al., Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain ofToxomplasma gondiiin vitro,Exp. Parasitol. 78(4):361-370 (1994).
Tomavo S et al., Characterization of bradyzoite-specific antigens ofToxoplasma gondii, Infect. Immun. 59(10):3750-3753 (1991).
Young JC et al., Hsp90: a specialized but essential protein-folding tool,J. Cell Biol. 154(2):267-273 (2001).
Angel Sergio O.
Echeverria Pablo C.
Matrajt Mariana L.
Nickol Gary B.
Shahnan-Shah Khatol
The University of Vermont and State Agricultural College
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for treating toxoplasma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating toxoplasma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating toxoplasma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694079